|
|
Volumn 3, Issue 1, 2002, Pages 6-
|
|
FDA licences imatinib mesylate for CML
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
CYTARABINE;
IMATINIB;
ADVANCED CANCER;
CANCER STAGING;
CANCER SURVIVAL;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG POTENTIATION;
DRUG TOLERABILITY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LICENCE;
MAJOR CLINICAL STUDY;
MEDICAL DECISION MAKING;
NOTE;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT FAILURE;
|
|
EID: 0036165807
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(01)00608-8 Document Type: Note |
|
Times cited : (29)
|
|
References (0)
|